Compare IMMP & OSPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMP | OSPN |
|---|---|---|
| Founded | 1987 | 1991 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2M | 390.0M |
| IPO Year | 2012 | 2000 |
| Metric | IMMP | OSPN |
|---|---|---|
| Price | $0.55 | $11.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $5.50 | ★ $16.67 |
| AVG Volume (30 Days) | ★ 867.5K | 508.4K |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.76% |
| EPS Growth | N/A | ★ 28.77 |
| EPS | N/A | ★ 1.88 |
| Revenue | N/A | ★ $243,180,000.00 |
| Revenue This Year | $417.85 | $3.22 |
| Revenue Next Year | N/A | $3.16 |
| P/E Ratio | ★ N/A | $5.81 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $10.07 |
| 52 Week High | $3.53 | $18.13 |
| Indicator | IMMP | OSPN |
|---|---|---|
| Relative Strength Index (RSI) | 36.54 | 58.11 |
| Support Level | N/A | $11.00 |
| Resistance Level | $1.75 | $11.54 |
| Average True Range (ATR) | 0.06 | 0.38 |
| MACD | 0.10 | 0.08 |
| Stochastic Oscillator | 36.05 | 84.47 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.